Clinical and radiographic outcomes of a monoblock fluted titanium tapered stem for paprosky IIIa, IIIb, and IV femoral bone defects
Passano B, Oakley CT, Lutes WB, Incavo S, Park KJ, Schwarzkopf R. Clinical and Radiographic Outcomes of a Monoblock Fluted Titanium Tapered Stem for Paprosky IIIa, IIIb, and IV Femoral Bone Defects [published online ahead of print, 2023 Jan 30]. J Arthroplasty. 2023;S0883-5403(23)00054-2. doi:10.1016/j.arth.2023.01.034
Background: Modern fluted titanium tapered stems (FTTS) have been increasingly utilized to achieve primary stability in conversion and revision total hip arthroplasty (rTHA) with major femoral bone loss. This study sought to determine the radiographic and clinical outcomes of a monoblock FTTS in patients who had major femoral bone loss.
Methods: A multicenter retrospective observational study of all THA patients who received a monoblock FTTS who had up to 5-year radiographic follow-up was conducted. Only patients with femoral Paprosky Classifications of IIIa, IIIb, and IV were included. Eighty-one monoblock FTTS were examined. Median clinical follow-up was 29 months (range, 18 to 58). Stem subsidence and loosening were assessed on most recent radiographs. All-cause revisions and stem survivals were assessed.
Results: Median subsidence was 1.4 millimeters(mm) (range, 0 to 15.0). Sixteen (23.9%) and three (4.5%) stems had subsidence greater than 5 and 10mm, respectively. All stems not acutely revised appeared stable, without evidence of loosening, at latest follow-up. Ten hips (12.3%) required reoperations. Of these, only 5 (6.2%) stems were removed; 4 due to periprosthetic joint infection and 1 for surgical exposure during acetabular revision. Kaplan-Meier analyses yielded an all-cause stem survivorship of 95.1% at 2-years and 87.1% at 4-years. Stem survivorships excluding septic causes was 98.8% at both 2 and 4 years.
Conclusion: Monoblock FTTS in complex femoral reconstruction cases showed encouraging clinical and radiographic results in patients who had severe femoral bone loss at median 29 months follow-up.
Aurora Health Clinic, Kenosha